Shares of Strides Pharma Science Ltd. jumped 3% after the company announced that its subsidiary, Strides Pharma Global Pte. Limited, Singapore, received USFDA approval for Fluoxetine Tablets 60 mg.
With this approval, Strides is now set to offer a complete portfolio of fluoxetine in 10 mg, 20 mg, and 60 mg strengths for both tablets and capsules.
The fluoxetine market, valued at around US$ 130 million, offers significant growth potential. Strides plans to launch all three strengths soon, with manufacturing set to take place at its Puducherry facility. This addition will enhance dosing flexibility and cater to a broader range of patient needs.
As of 3:22 pm the shares of Strides Pharma Science were trading 2.98% higher at ₹1,395.00 on NSE.
TOPICS:
Strides Pharma